Unknown's avatar

About Anna Meldolesi

science writer

Baby KJ in Nature’s Top Ten

Every December, Nature selects the 10 people of the year, those who have most shaped the year that is coming to an end. For 2025, the little KJ Muldoon, about whom we have written many times, could not be left out. The first newborn to receive a CRISPR treatment developed specifically for him, the inspiration for new rules on the testing of advanced therapies for rare diseases, the mascot that patients, families, doctors, and scientists needed to look to the future of medical editing with renewed confidence.

Playing with Chromosomes: CRISPR’s New Frontier

Humans have 23 pairs of chromosomes. The record-holder among animals (a butterfly called Polyommatus atlantica) can boast 229. Some plants have even more, but only because their genomes have undergone multiple rounds of duplication. We’re talking about chromosomes, of course. Their number is characteristic of each species and still shrouded in mystery. Why that number? And what would happen if we changed it?
In animals, the effects tend to be detrimental: mice with fused chromosomes, for instance, show abnormalities in behavior, growth, and fertility. Plants, however, appear surprisingly flexible, as demonstrated by a new experiment using CRISPR, recently published in Science.

Continue reading

Can CRISPR resurrect Neanderthals?

After the uproar over the de-extinction of dire wolves, bioethicist Arthur Caplan asked in Plos Biology: “Should scientists be allowed to bring distant human ancestors back to life?” The Italian edition of Scientific American invited me to investigate how technically difficult it would be to de-extinct a Neanderthal and what the risks and benefits of such a project might be. Below are the statements provided by the specialists I consulted.

Continue reading

The FDA charts a new route for bespoke therapies

Inspired by the Baby KJ case, the agency proposes a flexible framework allowing personalized treatments for individual patients to contribute to shared, platform-based approvals.

The announcement appeared on November 12 in the New England Journal of Medicine under a seemingly cautious title: “The FDA’s New Plausible Pathway.” Yet the article, written by two senior figures at the Food and Drug Administration, reveals vision and leadership. For once, it is worth starting from the end, which reads like a strong statement of intent: “Nearly 30 years after the sequencing of the human genome, bespoke therapies are close to reality. The FDA will work as a partner and guide in ushering these therapies to market, and our regulatory strategies will evolve to match the pace of scientific advances.”

Continue reading

Edited and polyselected babies: what’s going on?

An investigation by The Wall Street Journal has looked into Silicon Valley companies pushing the most controversial frontiers of assisted reproduction. It combines two rather different themes. Number one: the production of numerous embryos from which to choose based on a polygenic score that includes predispositions to hundreds of diseases and even a handful of desirable non-medical traits. Number two: gene-editing of embryos (also known as heritable or germline editing), which we’ve discussed many times since the case of the CRISPR babies in China and which now seems to be gaining new ground (the most talked-about company in this field is called Preventive).

Continue reading

Jennifer and Jim: Mr. DNA told by Lady CRISPR

The fascination with biochemistry sparked by The Double Helix, the thrill of her first invitation to Cold Spring Harbor, and the melancholy of her last visit to the disgraced genius.

While we wait for Nathaniel Comfort’s upcoming biography of James Watson, Jennifer Doudna’s story in The Code Breaker by Walter Isaacson offers a revealing lens on the scientist whose outstanding legacy is overshadowed by his offensive claims about intelligence and race. Doudna crossed paths with Watson three times — moments that shaped both her imagination and her opinion of the man who helped discover the structure of DNA.

Continue reading

Can technology replace animal testing?

New Approach Methodologies (NAMs) have a bright future ahead, but they should be seen as complementary rather than alternative to classical experimentation.

Regulatory and funding agencies in the U.S. and Europe are promoting ambitious initiatives to foster the development and adoption of advanced systems capable of testing the effects of drugs and other substances without using animal models. The hope is that biomedical research can become more ethical, safer, and cheaper. But the challenge is complex, and the requirements vary depending on the application. As a result, some voices urge a faster “transition,” while others warn that rushing the process could be risky. Recently published articles in leading scientific journals capture this polarized debate, but they also hint at a possible middle ground.

Continue reading

Baby KJ Effect: the new horizon of bespoke CRISPR therapies

The FDA is set to authorize “umbrella” clinical trials for rare diseases; the new approach will make the process faster and more sustainable by combining data from similar protocols, cutting redundant procedures, and reducing animal testing.

Continue reading

CRISPR pigs resist swine fever virus

At the Roslin Institute of the University of Edinburgh – the same research centre that created Dolly the sheep – scientists have used gene editing to achieve a new advance in animal breeding. With a precise CRISPR tweak, they have produced pigs that are immune to a highly contagious and often deadly viral disease: classical swine fever.

Continue reading

From skin cells to life: the future of artificial gametes

The progress achieved in Japan through experiments on mice has shown the way forward, but replicating these results in humans will pose technical, ethical, and legal challenges

Gametogenesis is the process by which gametes — male and female sex cells — are formed. In nature, it occurs inside the testes and ovaries, starting from progenitor cells that receive a variety of signals. Replicating the process in vitro is already possible in mice, albeit with low efficiency. Some specialists expect that within a decade, knowledge and technology will have advanced enough to apply these methods to humans, producing both sperm and eggs from cells taken from other parts of the body, and from individuals of either sex. This could allow infertile couples to have genetically related children without external donors, but it would also open the door to troubling new scenarios.

Continue reading